Martin Gleave, MD

Dr. Gleave is a Distinguished Professor and Chair of the Department of Urologic Sciences at the University of British Columbia. A clinician-scientist and urologic surgeon who has published more than 600 research papers, Dr. Gleave has raised over $120M in funding and co-founded biopharma startup OncoGenex, which was successfully acquired in 2017. In 2018, he was appointed to the Order of Canada for his research into cancer treatment resistance and developing new treatments for prostate cancer.